The Worldwide Diabetic Retinopathy Industry is Expected to Reach $7.7 Billion by 2027 at a 11.3% CAGR – Yahoo Finance

Share Article

DUBLIN, Nov. 22, 2022 /PRNewswire/ — The “Global Diabetic Retinopathy Market Size, Share & Industry Trends Analysis Report By Type, By Treatment Type, By Regional Outlook and Forecast, 2021-2027” report has been added to’s offering.
The Global Diabetic Retinopathy Market size is expected to reach $7.7 billion by 2027, rising at a market growth of 11.3% CAGR during the forecast period.

Diabetic retinopathy is a critical medical disorder that affects the eyes as a result of diabetes or inefficient insulin level in the blood of the patient. Impairment to blood vessels of the light-sensitive tissue of the retina is the main cause of diabetic retinopathy. In addition, blurred vision, dark or empty spots in the vision, fluctuating vision, poor color identification, and vision loss are the most typical symptoms of this disorder.
A high sugar level in the blood causes blockage of the retina’s small blood capillaries, impeding blood flow. Advanced cases of diabetic retinopathy require laser therapy or surgical operations. Mild-to-moderate instances of diabetic retinopathy can be cured with appropriate diabetes management.

Diabetic retinopathy may cause no symptoms or just minor vision abnormalities in the initial stages, however, it can result in blindness in advance stages. Anyone with type 1 or type 2 diabetes can develop the illness. The longer a person has diabetes, the more likely they are to develop ocular complications due to poorly regulated blood sugar levels. Diabetic retinopathy can progress to diabetic retinal detachment, macular edema, and neovascular glaucoma, among other serious eye disorders.

Diabetic retinopathy can also mutate to proliferative diabetic retinopathy, which is a more severe form of the disorder. Affected blood vessels close off in this type, leading the retina to develop new, dysfunctional blood vessels. These new blood vessels are fragile, and they may leak into the clear, jellylike fluid that fills the center of the eye of the patient.
Non-proliferative diabetic retinopathy, NPDR, is a kind of diabetic retinopathy in which symptoms are minimal or absent. New blood vessels are weakened or stop forming in this more prevalent form of diabetic retinopathy. The membranes of the blood vessels in the retina deteriorate when a patient suffers NPDR. Small bulges emerge from the smaller vessels’ walls, occasionally blood and seeping fluid into the retina. Larger retinal vessels may also begin to dilate and their size becomes irregular.

COVID-19 Impact Analysis

The COVID-19 pandemic caused a severe impact to various economies all over the world. Several businesses were significantly devastated as a result of the outbreak of the COVID-19 infection. In addition, the governments of several countries were forced to impose lockdowns in their nations.
As a result, the manufacturing units of numerous goods were temporarily shut. Moreover, these lockdowns also caused a major disruption in the supply chain of various goods. Further, the COVID-19 led the worldwide healthcare industry to a significant failure due to the shortage of beds and oxygen in hospitals. The outbreak of COVID-19 all over the world has placed healthcare workflows in a disarray. Various industries, including numerous sub-domains of healthcare, have been forced to temporarily close their units because of the rising cases of infection.

Market driving Factors:

Rising number of diabetic patients

Diabetes is considered as the major origin of diabetic retinopathy. Therefore, an increase in the number of patients that are suffering from diabetes is expected to directly increase the demand for diabetic retinopathy treatments. In addition, there is a significant rise in the number of patients with diabetes, due to which, the requirement of diabetic retinopathy treatment is continuously increasing.
There is a significant number of people that are concerned about the damage that can be caused to their eyes by the occurrence of the diabetic retinopathy. The diabetic retinopathy market is expected to grow due to an increase in diabetes prevalence around the world. According to the National Center for Biotechnology Information, Diabetic retinopathy affected 126 million people in 2010, and it is expected to affect more than 191 million people by 2030.

Increasing geriatric population all over the world

Instances of the diabetic retinopathy are more common in geriatric people. The prevalence of this disorder is found to be more robust in people that are aging above 60.
Moreover, the number of elderly people is becoming significant and accounts for a substantial share of the population in nearly every country, affecting several aspects of society, including financial markets and labor, demand for goods and services, like housing, transportation, as well as social protection, along with family structures and intergenerational ties.
According to the United Nations Organization, the population of elderly people all over the world is expected to become more than double throughout the next three decades, reaching 1.5 billion by 2050.

Marketing Restraining Factor:

Lack of healthcare facilities in developing and under-developed economies

People residing in poor countries have lesser access to healthcare facilities than wealthy people, while the poor people have lesser access to healthcare services inside their own countries. In contrast, poor people in low- and Middle-income countries, or LMICs, are continuously disadvantaged in several aspects of access as well as their determinants.
Moreover, the healthcare sector in the least developed countries is poorly underfunded, and a vast majority of these countries are unable to provide basic and fundamental healthcare services to their citizens. This problem is most prevalent in under-developed and developing countries, where government’s investments on public security is increasing at the cost of healthcare expenditure.
Key Topics Covered:

Chapter 1. Market Scope & Methodology

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Strategies Deployed in Diabetic Retinopathy Market

Chapter 4. Global Diabetic Retinopathy Market by Type
4.1 Global Proliferative Market by Region
4.2 Global Diabetic Macular Edema (DME) Market by Region

Chapter 5. Global Diabetic Retinopathy Market by Treatment Type
5.1 Global Anti VEGF Drug Market by Region
5.2 Global Steroid Implants Market by Region
5.3 Global Laser Surgeries Market by Region
5.4 Global Vitrectomy Market by Region

Chapter 6. Global Diabetic Retinopathy Market by Region

Chapter 7. Company Profiles
7.1 Alimera Sciences, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expense
7.1.5 Recent strategies and developments: Partnerships, Collaborations, and Agreements: Geographical Expansions:
7.2 F. Hoffmann-La Roche Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments: Partnerships, Collaborations, and Agreements: Approvals and Trials:
7.3 Bausch Health Companies, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.3.5 Recent strategies and developments: Partnerships, Collaborations, and Agreements: Approvals and Trials:
7.4 Bayer AG
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments: Approvals and Trials:
7.5 Pfizer, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional & Segmental Analysis
7.5.4 Research & Development Expense
7.6 Novartis AG
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.7 Allergan PLC (AbbVie, Inc.)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments: Partnerships, Collaborations, and Agreements:
7.8 Regeneron Pharmaceuticals, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Research & Development Expense Approvals and Trials:
7.9 Ampio Pharmaceuticals, Inc.
7.9.1 Company Overview
7.10. Kowa Company, Ltd.
7.10.1 Company Overview
For more information about this report visit
Media Contact:
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:
SOURCE Research and Markets
Veru (NASDAQ: VERU), a biopharmaceutical company that looks for novel cancer therapies, particularly in breast cancer or prostate cancer, saw its shares drop 10.33% on Monday. The company's stock already lost $10 a share two weeks ago when a Food and Drug Administration (FDA) advisory panel voted 8-5 against approving sabizabulin, Veru's COVID-19 oral therapy, via the Emergency Use Authorization route. It's not the last word, but the FDA usually agrees with advisory panels' votes.
Workers are lying about being digital nomads, and it's coming at a cost: One boss estimated his loss at $500,000.
(Bloomberg) — Cancer drugmaker Mirati Therapeutics Inc. is attracting fresh takeover interest from large pharmaceutical companies ahead of updates on its drug pipeline, people with knowledge of the matter said. The stock rose as much as 16% on the news. Most Read from BloombergHow Bad Will Housing Get? The Chill Gripping a Once-Hot Market Offers a TestMalaysia Latest: Muhyiddin Turns Down King on Unity GovernmentElon Musk's 2022 Wealth Loss Exceeds $100 Billion for First TimeFTX Latest: Key Tak
Henrik Fisker, the CEO of his eponymous EV company, rang the opening bell at the NYSE today to mark a huge milestone for the company. Last week at contract manufacturer Magna’s sprawling plant in Graz, Austria, the company began initial production of its Ocean EV SUV.
Bob Iger stunned the entertainment industry when he reassumed his role as the CEO of the Walt Disney Company on Sunday night. The former Disney chief will earn a $1 million base salary for going back to his old job, according to public filings. But that pact could grow a lot richer if Iger and […]
By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Data supports moving ahead with NASH clinical studies… Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) has multiple clinical development programs underway. ORMD-0801, ORMP’s lead development candidate, is being tested in diabetes in dual concurrent Phase 3 studies of ORMD-0801 for the treatment of T2D and in NASH. We believe Oramed’s multiple
There are another two weeks to go for the OPEC+ meeting, but the Saudis and Russians have decided not to sit back and let the market collapse continue. In an urgent response to a Wall Street Journal story on Monday, Saudi Energy Minister Abdulaziz bin Salman denied that the 23-nation oil producing alliance under his charge was working on a production hike of 500,000 barrels per day to announce at OPEC+’s Dec. 4 meeting. If the WSJ report had been true, it would have been a pivot to the 2-million-barrel per day cut that OPEC+ had announced for November.
Former FTX CEO Bankman-Fried did not address concerns about customer funds being misappropriated or other recent revelations about the company.
The prospect of a European embargo and a price cap on Russian oil, along with rising winter demand, are weighing on the production group.
Financial planners typically advise you to work for as long as you can, so you can juice up your retirement savings while holding out for a fatter Social Security check. Here’s the truth: Retiring early—or even at full retirement age—is little more than a joke for those tens of millions. It’s flaws like this—the refusal of increasingly more companies to shift the finances of retirement off their balance sheets and onto the backs of their workers—that mean millions have to keep working whether they’d like to or not.
Koninklijke Philips NV (NYSE: PHG) flagged further problems with some ventilator machines it had previously replaced. A Philips spokesperson said only Trilogy 100/200 ventilator models were potentially affected. The FDA said the company had notified that the new silicone sound abatement foam, installed in the reworked ventilators to replace the polyester-based polyurethane (PE-PUR) foam, may potentially separate from the plastic backing and could potentially block the air inlet and thus lower th
Saving $1 million (or more) for retirement is a great goal to have. Putting that much aside could make it easier to live your preferred lifestyle when you retire, without having to worry about running short of money. However, not … Continue reading → The post What Percentage of Retirees Have a Million Dollars? appeared first on SmartAsset Blog.
Almost all Americans should wait beyond the age of 65 to claim their full Social Security benefits.
The average 401(k) balance has dropped 23% from a year ago. That has big implications for baby boomers who recently retired or are about to.
CEL-SCI Corporation (NYSE: CVM) said that its 10-year Phase 3 trial showed that Multikine immunotherapy significantly extended the lives of patients with locally advanced primary squamous cell carcinoma of the head and neck (SCCHN). The company says that current drug therapies for SCCHN from Merck & Co Inc (NYSE: MRK) and Bristol Myers Squibb & Co (NYSE: BMS) are approved as a last resort. The Multikine treated study population showed the following advantages over control: A median overall survi
The wording even specified that nobody with a "familial relationship" with SBF or the recently fired execs would receive payment from FTX.
Reuters China To Reportedly Impose Over $1B Fine On Jack Ma's Ant Group Ending 2-Year Long Regulatory Overhaul Ending Jack Ma's Ant Group's two-year-long regulatory feud, Chinese authorities will reportedly impose a fine of more than $1 billion on the billionaire's fintech company. China's central bank – which has been driving the revamp at Ant after the Xi Jinping-led administration scuttled the company's $37 billion IPO at the last minute in 2020 – is the regulator readying the fine. Warren Bu
(Bloomberg) — Intel Corp. executive Randhir Thakur, who oversaw a key part of the company’s comeback plan — its push into the contract-manufacturing industry — is leaving the chipmaker. Most Read from BloombergHow Bad Will Housing Get? The Chill Gripping a Once-Hot Market Offers a TestMalaysia Latest: Muhyiddin Turns Down King on Unity GovernmentElon Musk's 2022 Wealth Loss Exceeds $100 Billion for First TimeFTX Latest: Key Takeaways From Tuesday’s Bankruptcy HearingStocks, Bonds Rally With F
The Oracle of Omaha doesn't believe diversification is necessary if you know what you're doing.
Shares of MacroGenics (NASDAQ: MGNX) were down more than 18% in early trading on Tuesday. Last week, the company's shares rose when it got word that a $60 million milestone payment was coming its way after the Food and Drug Administration approved the Biologics License Application (BLA) for teplizumab to delay the onset of type 1 diabetes. MacroGenics developed the drug, but it was purchased by Provention Bio in 2018.


You might also like

Surviving 2nd wave of corona

Surviving The 2nd Wave of Corona

‘This too shall pass away’ this famous Persian adage seems to be defeating us again and again in the case of COVID-19. Despite every effort